Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 13,196 call options on the stock. This represents an increase of ...

Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals (NASDAQ:RVPH). And retail traders should know. We noticed this today when the trades showed up on ...

Reviva Pharmaceuticals Holdings Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 90.48%. The profit margin, also known as the revenue ratio or gross ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage ...

EF Hutton has initiated coverage on Reviva Pharmaceuticals (NASDAQ: RVPH), issuing a Buy rating with a price target of $15.00. The firm's optimism is primarily driven by the ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.